The Translational-Predictive-Adaptive methodology: a Systems-Biology framework for Redox-Driven Host optimization and Terrain priming in CAR T-Cell therapy

IMPORTANT LEGAL NOTICE & RESEARCH STATUS This document presents a Theoretical Systems-Biology Framework (Level V Evidence) intended for academic discussion and future clinical research. The author, Valentina Luongo (Consultant in Scientific Naturopathy), provides this methodology as an intellectual contribution to translational medicine. This is NOT medical advice, diagnosis, or clinical prescription. Implementation of the TPA Methodology strictly requires the supervision, calibration, and legal responsibility of licensed medical doctors and must be conducted within authorized clinical settings. EXECUTIVE SUMMARY Background and Rationale Contemporary immunotherapeutic strategies for Multiple Myeloma (MM) — most notably Chimeric Antigen Receptor (CAR) T-cell therapies — represent a paradigm-defining advance in haematological oncology. Yet their clinical efficacy remains constrained by three converging biological failures: hostile bone marrow microenvironments, blood-brain barrier (BBB) instability, and progressive T-cell metabolic exhaustion. The aggregate consequence is a high rate of treatment failure, severe immune-mediated toxicity, and relapse, despite investments exceeding USD 350,000 per therapeutic dose. Objective This work presents the Translational-Predictive-Adaptive (TPA) Methodology, a novel theoretical framework designed to address the biological gaps limiting CAR-T efficacy in MM. The model proposes the integrated study of Molecular Hydrogen (H2) — designated here as a Gaseous Biophysical Vector — in combination with modeled adaptive phenotyping and hypothetical chrono-nutritional protocols. Methods The TPA Methodology is conceptualized across three sequential and interdependent phases: (1) Niche Priming, a proposed 14-day pre-infusion hydrogenomic framework intended for research on host pre-habilitation, theoretically employing H2 to reset the bone marrow redox potential of the bone marrow niche; (2) Barrier Stabilisation — real-time modulation of endothelial tight junction proteins (Zonula Occludens-1, Occludin) and Nrf2 pathway upregulation to prevent BBB degradation and consequent Immune Effector CellAssociated Neurotoxicity Syndrome (ICANS); and (3) Metabolic Persistence Engineering — facilitation of a metabolic switch from anaerobic glycolysis to Fatty Acid Oxidation (FAO) to promote the generation of long-lived memory T-cell subsets (Tscm and Tcm). Patient stratification is governed by an Adaptive Phenotyping Matrix that classifies individuals into three metabolic risk clusters — Hyper-Reactive, Neuro-Vulnerable, and Metabolic-Stasis — determining the duration and dosage of hydrogenomic loading accordingly. Key findings and theoretical contributions The framework proposes that the predominant cause of CAR-T failure in MM is not cellular engineering inadequacy but terrain hostility — a concept operationalised through the translational decoding of biological systems terminology into the molecular language of oncology, bioenergetics, and redox physiology. The methodology constitutes, to the best of the author's knowledge, the first formal integration of systems-biology adaptive phenotyping with Hydrogenomics in a predictive-adaptive clinical model for haematological malignancies. Clinical and Economic Implications Successful implementation of the TPA Method is projected to reduce ICU admissions attributable to CRS and ICANS, preserve the efficacy of the CAR-T biological asset, and contribute to a model of stabilised disease chronicity — redefining oncological remission as durable immunosurveillance rather than episodic cytoreduction.